CellGer Biotechnology was founded in 2016, headquartered in Hangzhou. It is an in vitro diagnostic enterprise focused on the innovation of new immune detection technologies and the research and application of detection platforms. CellGer Biotechnology has the first domestic multi indicator cytokine combined detection kit, the first approved registration of programmed death protein-1 (PD-1) kit, exclusive registration of tumor associated diagnostic factors, soluble inflammatory factors, and chemokines combined detection kits, immunoglobulin G subclasses, Alzheimer's disease detection kits, and more than 200 flow cytometry matching reagents.
Since its establishment, the company has continuously made breakthroughs and innovations, and has been awarded multiple honors such as "High tech Enterprise Certification", "Top 10 Enterprise Growth Stars", and "Specialized, Refined, Unique, and New" Small and Medium sized Enterprises in Jiangxi Province. It has also been selected as a "Quasi Unicorn" in Hangzhou for three consecutive years. The company has always been based on independent innovation, striving to become a high-tech company with international influence in the field of clinical diagnosis with the highest quality products and services, and making contributions to the cause of human health.
